A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide. (December 2016) - Denmeade, S.; Antonarakis, E.; Paller, C.; Wang, H.; Benjamin, T.; Drake, C.; Carducci, M.; Eisenberger, M.